ICICI Prudential Pharma Healthcare & Diagnostics IDCW Payout Direct Plan
SIP amount
Temporarily restricted by fund house
Lumpsum amount
Temporarily restricted by fund house

ICICI Prudential Pharma Healthcare & Diagnostics IDCW Payout Direct Plan

NAV
₹26.1700
+0.23%
(12 Dec)
AUM
6,460 Cr
TER
1.03%
Risk
Very High Risk
Insights
Net Asset Value (NAV) is below its 200 days moving average
Asset Under Management (AUM) is in the top 25% of comparable funds
Total Expense Ratio (TER) is in the top 25% of comparable funds
In beta. Send feedback here.
Compare with other fund
1Y
+3.4%
+3.4%
-0.0%
-0.0%
-0.0%
3Y
+27.5%
+27.5%
+28.1%
+28.1%
+28.1%
5Y
+18.8%
+18.8%
+23.9%
+23.9%
+23.9%
ALL
+21.3%
+21.3%
+17.6%
+17.6%
+17.6%
VOL
16.9%
16.9%
17.8%
17.8%
17.8%
TER
1.0%
1.0%
0.5%
0.5%
0.5%
AUM
₹6,460 Cr
₹6,460 Cr
₹8,189 Cr
₹8,189 Cr
₹8,189 Cr
INFO
1.26
1.26
0.99
0.99
0.99
Past performance
Past performance is no guarantee of future returns.
Had you invested
Over the last
1Y
3Y
ALL
Your returns would have been
ICICI Pru Pharma Healthcare & Diagnostics IDCW Payout (DP)
₹1,00,00,00,000
14.0%
Fixed deposit
₹40,00,00,000
6.0%
Bank savings
₹40,00,00,000
3.0%
See fund holdings as of 31st Oct
Top holdings
Sun Pharmaceuticals Industries Ltd
11.9%
Dr Reddy's Laboratories Ltd
9.4%
Divi's Laboratories Ltd
8.5%
Aurobindo Pharma Ltd
7.6%
Cipla Ltd
6.6%
Lupin Ltd
5.4%
Alkem Laboratories Ltd
4.0%
Biocon Ltd
3.3%
Treps
3.2%
Mankind Pharma Ltd
2.8%
Top industry exposure
Healthcare
94.8%
Basic Materials
1.2%
Financial Services
1.2%
Other information
Minimum SIP
Restricted (AMC)
Minimum lumpsum
Restricted (AMC)
Additional lumpsum
Restricted (AMC)
Portfolio turnover
61%
Lock-in period
-
Exit load
• 1% for redemption within 15 days
Fund objective
To generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. However there can be no assurance or guarantee that the investment objectives of the scheme would be achieved.
Fund manager(s)
Dharmesh Kakkad
Sharmila D’mello

FAQs